Geron (LTS:0IV3) Cyclically Adjusted Book per Share: $0.73 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0IV3 Geron Corp LTS:0IV3
46 GF Score
Price $1.25
GF Value $6.74
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Geron Cyclically Adjusted Book per Share?

Geron LTS:0IV3 -10.71% 46 Cyclically Adjusted Book per Share is $0.73 as of Mar. 2026. GuruFocus rates LTS:0IV3 with a GF Score™ of 46/100 and a GF Value™ of $6.74 (Possible Value Trap). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Geron's adjusted book value per share for the three months ended in Mar. 2026 was $0.357. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $0.73 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Geron's average Cyclically Adjusted Book Growth Rate was -7.50% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -3.30% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -3.20% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was -7.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Geron was 0.70% per year. The lowest was -12.90% per year. And the median was -5.25% per year.

As of today (2026-08-01), Geron's current stock price is $1.25. Geron's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $0.73. Geron's Cyclically Adjusted PB Ratio of today is 1.71.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Geron was 5.73. The lowest was 0.82. And the median was 1.77.


Geron  (LTS:0IV3) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Geron's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=1.25/0.73
=1.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Geron was 5.73. The lowest was 0.82. And the median was 1.77.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Geron Cyclically Adjusted Book per Share Related Terms


Geron Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Geron's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Geron Cyclically Adjusted Book per Share Chart

Geron Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.86 0.81 0.85 0.79 0.77

Geron Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.78 0.79 0.77 0.77 0.73

LTS:0IV3 vs PHAT, KURA, ODTX: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Geron's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Geron Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Geron's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Geron's Cyclically Adjusted PB Ratio falls into.


LTS:0IV3
46GF Score
Geron Corp LTS:0IV3
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Geron Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Geron's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.357/330.2130*330.2130
=0.357

Current CPI (Mar. 2026) = 330.2130.

Geron Quarterly Data

Book Value per Share CPI Adj_Book
201606 0.819 241.018 1.122
201609 0.810 241.428 1.108
201612 0.769 241.432 1.052
201703 0.737 243.801 0.998
201706 0.710 244.955 0.957
201709 0.680 246.819 0.910
201712 0.649 246.524 0.869
201803 0.629 249.554 0.832
201806 0.977 251.989 1.280
201809 0.985 252.439 1.288
201812 0.954 251.233 1.254
201903 0.909 254.202 1.181
201906 0.841 256.143 1.084
201909 0.790 256.759 1.016
201912 0.676 256.974 0.869
202003 0.603 258.115 0.771
202006 0.807 257.797 1.034
202009 0.750 260.280 0.952
202012 0.679 260.474 0.861
202103 0.632 264.877 0.788
202106 0.550 271.696 0.668
202109 0.473 274.310 0.569
202112 0.390 278.802 0.462
202203 0.301 287.504 0.346
202206 0.376 296.311 0.419
202209 0.284 296.808 0.316
202212 0.205 296.797 0.228
202303 0.641 301.836 0.701
202306 0.572 305.109 0.619
202309 0.536 307.789 0.575
202312 0.455 306.746 0.490
202403 0.583 312.332 0.616
202406 0.510 314.175 0.536
202409 0.485 315.301 0.508
202412 0.462 315.605 0.483
202503 0.421 319.799 0.435
202506 0.407 322.561 0.417
202509 0.390 324.800 0.396
202512 0.353 324.054 0.360
202603 0.357 330.213 0.357

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $0.73 mean?
Geron (LTS:0IV3) has a Cyclically Adjusted Book per Share of $0.73 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Geron and its competitors.
Is Geron's Cyclically Adjusted Book per Share too high?
Geron's current Cyclically Adjusted Book per Share is $0.73. Overall, Geron has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Geron's Cyclically Adjusted Book per Share compare to PHAT and KURA?
Geron's Cyclically Adjusted Book per Share of $0.73 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Geron and its competitors. Geron's current Cyclically Adjusted Book per Share is $0.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Geron stock overvalued right now?
Based on GuruFocus' analysis, Geron (LTS:0IV3) is currently considered Possible Value Trap. The stock's GF Value™ is $6.74, compared to a current price of $1.25 — trading 81.5% below its estimated fair value. The current Cyclically Adjusted Book per Share is $0.73. Geron's overall GF Score™ is 46/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Geron (LTS:0IV3), the current Cyclically Adjusted Book per Share is $0.73 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Geron (LTS:0IV3) Overvalued in 2026?

Based on GuruFocus' analysis, Geron stock appears to be undervalued. The current stock price of $1.25 is trading 81.5% below its estimated GF Value™ of $6.74. GuruFocus considers Geron to be Possible Value Trap.

Key valuation signals for LTS:0IV3:

  • Cyclically Adjusted Book per Share: $0.73
  • GF Value™: $6.74 vs. price of $1.25 (81.5% below fair value)
  • GF Score™: 46/100 with 4 warning signs

No single metric tells the full story. See the LTS:0IV3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Geron Business Description

Address 919 East Hillsdale Boulevard, Suite 250, Foster City, CA, USA, 94404
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
46GF Score

Get the complete analysis for LTS:0IV3

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.25
Price
$6.74
GF Value